Delivery Hero Shares Jump on Uber Takeover Offer at 33 Per Share Snowflake Stock Surges 36 on Earnings Beat and 6 Billion AWS Expansion Plan SP 500 Earnings Surge Historically Signals Caution for Investors Micron Stock Hits Major Milestone as UBS Highlights Strong Memory Chip Demand Forbes Reveals Top 10 Cryptocurrencies as of May 28 2026 Biotech and Pharma Stocks Decline Amid Rotation Into Energy Sector VVV Q1 2026 Earnings EPS Surges 18 Above Estimates Stock Climbs Fluor Corporation FLR Q1 2026 Earnings EPS Falls Sharply Below Estimates Despite Modest Share Gain Sunrun RUN Q1 2026 Earnings Solar Leader Posts Record EPS Surprise Shares Rally High Tide Inc Q1 2026 Earnings EPS Beat of 300 Fails to Lift Shares Amid Missing Revenue Disclosure ALRM Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher POWWP Q1 2026 Earnings Preferred Stock Delivers Positive Surprise with EPS Beat Aclarion Inc Warrant ACONW Declines Sharply Testing AllTime Low Territory Stereotaxis Inc STXS Shows Modest Uptick Testing Key Resistance Levels ITHAX Acquisition Corp III ITHA Edges Lower as SPAC Trades Near Trust Value Actelis Networks ASNS Inches Higher at 009 as Penny Stock Holds Key Support Waterstone Financial WSBF Holds Steady Near Support Modest Uptick Signals Consolidation USIran Standoff Deepens After Trump Rejects Counteroffer Raising Risks for Global Energy Markets Intergroup Corporation INTG Q1 2026 Earnings Positive EPS as Stock Advances Despite Sparse Disclosure Webull Warrants BULLW Slide 95 as Selling Pressure Intensifies Near Key Support XLO Q1 2026 Earnings Narrower Loss and Positive Stock Reaction Signal Progress GPK Q1 2026 Earnings EPS Surges 56 Above Estimates Stock Jumps 515 TLYS Q1 2026 Earnings Earnings Surprise with 165 EPS Beat Ionis Pharmaceuticals Q1 2026 Earnings EPS Beat Driven by Cost Discipline Stock Holds Steady SLSN Q1 2026 Earnings Loss Per Share of 001 as Shares Decline 234 PMCB Q1 2026 Earnings PreRevenue Biotech Reports Negative EPS Stock Rises on Potential Pipeline Progress ASND Q1 2026 Earnings EPS Misses Estimates as Ascendis Pharma Navigates Cost Pressures